A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myelogenous Leukemia

The purpose of this study is to evaluate the efficacy and safety of pevonedistat plus
azacitidine versus single-agent azacitidine in participants with HR-MDS or CMML, or low-blast
AML.

本研究旨在评估培妥奈司他（pevonedistat）联合阿扎胞苷（azacitidine）对比单药阿扎胞苷，针对高危骨髓增生异常综合征（High-Risk Myelodysplastic Syndromes，HR-MDS）、慢性粒单核细胞白血病（Chronic Myelomonocytic Leukemia，CMML）或低原始细胞急性髓系白血病（low-blast AML）受试者的疗效与安全性。